secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2024-09-26T23:59:59+00:00
Accession:  0001193125-24-226999
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Biopharma FY2024 net loss $22.4M, cash $50.9M; BB-301 shows swallowing improvement
--------------------------------------------------------------------------------

- Net loss of $22.4M ($5.51 per share) for FY2024; cash and equivalents $50.9M as of June 30, 2024.
- Oversubscribed $40M PIPE closed April 2024; cash runway extended through 2025.
- Interim data for first low-dose BB-301 subject showed clinically meaningful improvements in swallowing at 90 and 180 days; no SAEs.
- Second subject dosed Feb 2024; third subject expected Q4 2024.
- Kishen Mehta appointed to board effective June 26, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524226999/0001193125-24-226999-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524226999/d817476d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-226999

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer